filmov
tv
Dr. Leighl Discusses Binimetinib in KRAS-Mutated NSCLC
Показать описание
OncLive
cancer
oncology
Рекомендации по теме
0:02:25
Dr. Leighl Discusses Binimetinib in KRAS-Mutated NSCLC
0:02:35
Does targeted therapy mean I don't need chemotherapy?
0:00:33
Combination Encorafenib Plus Binimetinib in Patients With Melanoma
0:08:47
BRAF/MEK Inhibitors in Metastatic Melanoma
0:00:56
Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC
0:25:28
Dr Leighl LCPS Presentation - Navigating Lung Cancer Treatment
0:01:37
Binimetinib vs. Dacarbazine in NRAS-mutant Melanoma
0:01:17
Treatment selection for stage III BRAF-mutant melanoma
0:01:01
Findings from the NILE Study by Dr. Natasha Leighl
0:02:35
Brain metastases in ALK+ NSCLC
0:04:45
GMMG-Birma: BRAF and MEK inhibition in mutant BRAF V600E myeloma
0:00:57
Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients
0:00:49
Next Steps After Phase III BEACON CRC Trial in mCRC
0:13:48
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
0:21:10
Targeting HER2, BRAF, KRAS, MET
0:05:43
Advanced-Stage NSCLC: KEYNOTE-189’s Role in Treatment
0:01:24
Dr. Kennedy on RAS as a Target
0:02:38
Dr. Wolf Discusses the GEOMETRY Study in MET+ NSCLC
0:01:22
Dr. Brufsky on Cobimetinib Plus Paclitaxel in TNBC
0:14:45
Potential and progress in targeting less common markers: HER2, BRAF, KRAS, MET, TRK, and RET
0:02:38
Key lung cancer updates: KRAS(G12C) inhibitors and ADCs
0:01:48
SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations...
0:06:01
BEACON Trial: Triplet Therapy in BRAF V600E–Mutated mCRC
0:07:23
Targeted Therapy for KRAS-Mutant NSCLC
visit shbcf.ru
0:02:25
0:02:35
0:00:33
0:08:47
0:00:56
0:25:28
0:01:37
0:01:17
0:01:01
0:02:35
0:04:45
0:00:57
0:00:49
0:13:48
0:21:10
0:05:43
0:01:24
0:02:38
0:01:22
0:14:45
0:02:38
0:01:48
0:06:01
0:07:23